Soligenix initiates Phase 2 clinical trial of SGX945 in Behcet’s Disease

Soligenix (SNGX) has opened patient enrollment for its Phase 2 study evaluating SGX945 – dusquetide – in the treatment of Behcet’s Disease. Soligenix looks forward to completing enrollment and announcing study results in the first half of 2025. The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients age 18 years or older with mild to moderate Behcet’s Disease and active oral and/or genital ulcers. Efficacy endpoints will include the extent of lesion clearance, timeline to lesion clearance, and patient reported quality of life assessments.